Abstract
Gemfibrozil was found to be an effective hypotriglyceridaemic agent in types IV, IIb and V hyperlipoproteinaemia. When given at a dose level of 800 mg/day its activity was nearly of the same order of magnitude as 1.5 g/day of clofibrate.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cooper J., Geizerova H., Oliver M. F. Letter: Clofibrate and gallstones. Lancet. 1975 May 10;1(7915):1083–1083. doi: 10.1016/s0140-6736(75)91845-0. [DOI] [PubMed] [Google Scholar]
- Hess R., Stäubli W., Riess W. Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature. 1965 Nov 27;208(5013):856–858. doi: 10.1038/208856a0. [DOI] [PubMed] [Google Scholar]
- Pertsemlidis D., Panveliwalla D., Ahrens E. H., Jr Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology. 1974 Apr;66(4):565–573. [PubMed] [Google Scholar]
- Stone M. C., Thorp J. M., Mills G. L., Dick T. B. Comparison of membrane filtration and nephelometry with analytical ultracentrifugation, for the quantitative analysis of low density lipoprotein fractions. Clin Chim Acta. 1970 Dec;30(3):809–828. doi: 10.1016/0009-8981(70)90279-2. [DOI] [PubMed] [Google Scholar]